Objective-To introduce and monitor a screening programme for first degree relatives of patients with colorectal cancer based on their calculated lifetime risk.
Introduction
The lifetime risk of death from colorectal cancer in England and Wales is approximately 1 in 50 and increases rapidly from age 50. Unfortunately, the results of treatment are disappointing with an acknowledged survival rate of 50% in patients undergoing surgery with a view to cure. In 1974 Morson pointed out that most colorectal carcinomas arise in preexisting adenomatous polyps and this hypothesis of the adenoma-carcinoma sequence offers an opportunity for early diagnosis and treatment if polyps can be identified. ' Population screening using faecal occult blood tests, though low in cost, has so far been found to have a disappointing uptake and poor yield.2 A screening programme targeted at people at high risk should be more efficient. Furthermore, compliance is likely to be high among those who perceive themselves to be at increased risk and have a good understanding of the reasons for screening.
Family studies have shown that the risk of colorectal cancer in the first degree relatives ofaffected individuals is two to four times the risk in the general population. 3`6 Furthermore, a number of dominantly inherited syndromes associated with colorectal cancer are now recognised. Adenomatous polyposis coli is the best known and is recognised as the condition with the highest risk of bowel cancer. Other dominant conditions associated with a high risk of colorectal malignancy include site specific colonic cancer7 and a cancer family syndrome89 that is associated with an increased risk of uterine, breast, and other extracolonic cancers in addition to an increased risk of colonic cancer. These two non-polyposis cancer Table IV shows the number of relatives with varying risks, their ages, and the number in whom polyps or colorectal cancers were detected. In two relatives with a risk of 1 in 2 polyps were too numerous for control through colonoscopy and colectomy was performed. There was no evidence of adenomatous polyposis coli in either of these patients. Polyps were detected in nine relatives who were already known to have colonic cancer; two had metachronous colonic cancer. Eighteen relatives were screened by colonoscopy because, although their risks were less than 1 in 10, they reported rectal bleeding or had positive results on occult blood tests; three had polyps. Nine patients from three previously undiagnosed In a family cancer clinic obtaining risk estimates for first degree relatives of patients with colorectal cancer from family histories enabled screening to be offered to relatives based on their probability of developing colorectal cancer. We decided to talk to patients and their relatives frankly about their risks. Contact with other family members at risk was made only through the patients who attended the clinic. We were aware that anxieties might be heightened in this vulnerable population by discussing numerical risks and the possibility of malignancy, but in practice patients from high risk families attending the clinic seemed relieved to discuss their risks and take responsibility for their screening. Indeed, a remarkable feature of the patients who had referred themselves was the accuracy with which they had estimated their risk: 237 of 365 (65%) were in the high risk category. Of all 606 patients, 545 (90%) took up the offer of screening including examinations by colonoscopy, which involved time and discomfort.
Screening by faecal occult blood tests seems to be unsuitable for high risk patients as it has a poor negative predictive value, and this supports the observations of Rozen et al. '5 Colonoscopy, however, is an efficient method of detecting malignant polyps. In our series polyps were detected and removed through the regular screening programme in 62 of 382 (16%) patients in the high risk groups. The young age of the patients and the right sided distribution of the polyps were consistent with the observations of other workers'°121316 and support the view that colonoscopy is an appropriate screening method for this high risk group.5 16 The high proportion of patients with family histories compatible with the Lynch types I and II cancer family syndrome was not wholly unexpected; their contribution to the overall incidence of colonic cancer has been estimated as 6-10%.'°Twenty seven per cent of the patients who presented to the family cancer clinic because they had recognised the high frequency of bowel cancer in their family had pedigrees compatible with these Lynch cancer family syndromes. Any strategy targeting patients at high risk of colorectal cancer for screening must recognise that screening of the breasts and pelvis should be available to patients from families with Lynch type II cancer family syndrome.
Seven out of 14 patients over 65 with a risk of 1 in 2 who were screened were found to have colonic polyps on colonoscopy, contrasting with an estimate from the results of postmortem examination of 37-70%. 1718 One patient, however, had a carcinoma in situ. These patients were not included in a regular screening programme because they were over 65, but they were offered colonoscopy for clinical management because their risk was high and the result would contribute to the genetic information relevant to other family members. The numbers are too small to draw any conclusion about the possible benefits of screening older relatives, but the question may merit further consideration.
We conclude that by taking a careful family history it is possible-to identify people at increased risk of colorectal cancer and that screening by colonoscopy to detect premalignant polyps is appropriate for high risk patients. Furthermore, targeting such high risk patients may make better economic use of available screening facilities than large scale population screening.
The economic benefits of screening the high risk groups cannot be estimated until long term 
